AGLE - Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement
- Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options.
- Aeglea's pipeline consists of two clinical-stage therapeutics and one in the late-pre-clinical stage covering primarily metabolic enzyme-related indications including arginase 1 deficiency, the indication of its lead Phase 3 therapeutic, Pegzilarginase.
- Aeglea is currently in a strong financial position with $128.5M worth of cash (March 2021) alongside a TTM cash burn of -$77M and company guidance outlining funding into 2023.
- Aeglea's next major catalyst is the pivotal topline Phase 3 data announcement expected in 4Q2021.
- In summary, the author projects Aeglea BioTherapeutics, Inc. as a "buy" at a 2-3 year price target of $14.43 (+89% upside).
For further details see:
Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement